IN2012DN01878A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN01878A IN2012DN01878A IN1878DEN2012A IN2012DN01878A IN 2012DN01878 A IN2012DN01878 A IN 2012DN01878A IN 1878DEN2012 A IN1878DEN2012 A IN 1878DEN2012A IN 2012DN01878 A IN2012DN01878 A IN 2012DN01878A
- Authority
- IN
- India
- Prior art keywords
- cancer
- diseases
- administration
- prevention
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also disclosed.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27575409P | 2009-09-02 | 2009-09-02 | |
| PCT/US2010/047615 WO2011028860A2 (en) | 2009-09-02 | 2010-09-02 | Compounds and compositions for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN01878A true IN2012DN01878A (en) | 2015-08-21 |
Family
ID=43625764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1878DEN2012 IN2012DN01878A (en) | 2009-09-02 | 2010-09-02 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2473506A4 (en) |
| JP (1) | JP2013503888A (en) |
| KR (1) | KR20120104165A (en) |
| CN (1) | CN102625805A (en) |
| AU (1) | AU2010289493A1 (en) |
| BR (1) | BR112012004701A2 (en) |
| CA (1) | CA2772614A1 (en) |
| IN (1) | IN2012DN01878A (en) |
| WO (1) | WO2011028860A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101629642B1 (en) | 2014-06-25 | 2016-06-13 | 서울대학교산학협력단 | Food composition, pharmaceutical composition, animal medicine and feed composition against fatty liver with piperlongumine |
| GB201715008D0 (en) * | 2017-09-18 | 2017-11-01 | Inst De Medicina Molecular Faculdade De Medicina Univ De Lisboa | TRPV2 Antagonists |
| KR20200081633A (en) | 2018-12-27 | 2020-07-08 | 주식회사 티에스디라이프사이언스 | A pharmaceutical composition for treatment or prevention of biliary atresia comprising piperlongumine |
| CN110002987B (en) * | 2019-03-22 | 2020-09-15 | 南通大学 | Phenylallylidene cyclohexenone derivative, preparation method and application thereof |
| CN117229205A (en) * | 2023-09-14 | 2023-12-15 | 中国医学科学院基础医学研究所 | Preparation method and pharmaceutical application of phenyl acrylamide RHbDD1 inhibitor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2478901A3 (en) | 2007-02-14 | 2012-11-14 | Mars Incorporated | Neurogenic compounds |
| EP2135078B1 (en) * | 2007-03-09 | 2013-08-21 | DiscoveRx Corporation | Methods for identifying agents and their use for the prevention or stabilization of fibrosis |
| CN102146054A (en) * | 2010-02-10 | 2011-08-10 | 新昌县来益科技开发有限公司 | Piperlongumine derivatives and medicinal composition and application to preparation of medicament for inhibiting tumor growth thereof |
-
2010
- 2010-09-02 KR KR1020127007113A patent/KR20120104165A/en not_active Application Discontinuation
- 2010-09-02 JP JP2012528029A patent/JP2013503888A/en active Pending
- 2010-09-02 CA CA2772614A patent/CA2772614A1/en not_active Abandoned
- 2010-09-02 AU AU2010289493A patent/AU2010289493A1/en not_active Abandoned
- 2010-09-02 WO PCT/US2010/047615 patent/WO2011028860A2/en active Application Filing
- 2010-09-02 EP EP10814469A patent/EP2473506A4/en not_active Withdrawn
- 2010-09-02 CN CN2010800418987A patent/CN102625805A/en active Pending
- 2010-09-02 BR BR112012004701A patent/BR112012004701A2/en not_active IP Right Cessation
- 2010-09-02 IN IN1878DEN2012 patent/IN2012DN01878A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2473506A4 (en) | 2013-03-06 |
| AU2010289493A1 (en) | 2012-04-19 |
| WO2011028860A2 (en) | 2011-03-10 |
| CN102625805A (en) | 2012-08-01 |
| KR20120104165A (en) | 2012-09-20 |
| BR112012004701A2 (en) | 2018-06-12 |
| CA2772614A1 (en) | 2011-03-10 |
| JP2013503888A (en) | 2013-02-04 |
| WO2011028860A3 (en) | 2011-07-21 |
| EP2473506A2 (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY157124A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| WO2012024530A3 (en) | Therapeutic peptide-polymer conjugates, particles, compositions, and related methods | |
| WO2009114703A3 (en) | Combination therapy for the treatment of cancer | |
| WO2011082273A3 (en) | Substituted pyrrolo-aminopyrimidine compounds | |
| WO2011082267A3 (en) | Substituted triazolo-pyrazine compounds | |
| MX2011006959A (en) | Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds. | |
| SG10201811480WA (en) | Therapeutic compounds and compositions | |
| WO2011082266A3 (en) | Substituted heterocyclic compounds | |
| UA107783C2 (en) | Isoindoline compounds for use in treating cancer | |
| MY162903A (en) | Methods of treatment of pancreatic cancer | |
| MX2012010434A (en) | Novel compounds and compositions for targeting cancer stem cells. | |
| IL207310A0 (en) | Vaccine compositions | |
| MX2019000547A (en) | Stabilized liquid and lyophilized adamts13 formulations. | |
| WO2010059004A3 (en) | Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient | |
| WO2010132697A3 (en) | Methods and compositions for treatment | |
| WO2011123678A3 (en) | Substituted benzo-pyrido-triazolo-diazepine compounds | |
| WO2011129936A3 (en) | Compositions and methods for the prevention and treatment of cancer | |
| WO2011082268A3 (en) | Substituted naphthalenyl-pyrimidine compounds | |
| WO2010097788A3 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| IN2012DN01878A (en) | ||
| NZ595440A (en) | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds | |
| MY164998A (en) | Isoquinolinone derivatives as nk3 antagonists | |
| WO2011044523A3 (en) | Compositions and methods for treating obesity | |
| WO2011100330A3 (en) | Compositions and methods for preventing or treating a human parvovirus infection | |
| MX2012003729A (en) | Oral composition for treating oral malodor. |